Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Novelion Therapeutics Inc's Business Segments
Novelion Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 32
Regions Reported
-
Novelion Therapeutics Inc does not report a distinct business-segment axis in its filings - its disaggregated revenue is disclosed by product and service category instead. See the Product & Service breakdown below.
Revenue by Product & Service Category - FY
- Product63.7%
- Metreleptin35.5%
- Lomitapide28.2%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 21 | 63.7% |
| Metreleptin | $ 11 | 35.5% |
| Lomitapide | $ 9 | 28.2% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Novelion Therapeutics Inc
Novelion Therapeutics Inc. is a biopharmaceutical company that mainly focuses on the development and commercialization of drugs to treat patients with rare diseases. The company was formerly known as QLT Inc. It was founded in 1981 and is headquartered in Vancouver, Canada.
Novelion Therapeutics Inc. has a strong portfolio of products in various stages of development for treating rare diseases, including genetic disorders and complex lipid storage disorders. The company’s lead drug, Aegerion’s JUXTAPID® (lomitapide), is FDA approved and used to treat homozygous familial hypercholesterolemia (HoFH) - an ultra-rare genetic condition that affects fewer than one in a million people. JUXTAPID® is designed to reduce cholesterol levels in patients by blocking the production of low-density lipoprotein (LDL) - a type of harmful cholesterol.
Apart from their lead drug, Novelion Therapeutics has other promising drugs in their pipeline, including myalept® (metreleptin) - a treatment for lipodystrophy, which is currently FDA approved, and zuretinol acetate (QLT091001) for the treatment of the rare inherited retinal disease, Leber congenital amaurosis. Additionally, the company is developing a pipeline of treatments for other genetic diseases with unmet medical needs, such as late-onset LAL deficiency (Wolman disease and cholesteryl ester storage disease [CESD]), and Alagille syndrome, among others.
Novelion Therapeutics works closely with regulatory bodies, including the FDA, to ensure smooth and efficient product development and approval processes. The company's management team comprises seasoned executives who bring a vast amount of experience in different pharmaceutical sectors, including business development, operations, clinical development, and regulatory affairs.
In conclusion, Novelion Therapeutics Inc. is a biopharmaceutical company that is focused on developing and commercializing innovative treatments for rare genetic disorders. Their strong product portfolio, experienced leadership team, and commitment to working with regulatory bodies make them a promising company in the field of rare diseases.
Novelion Therapeutics Inc. has a strong portfolio of products in various stages of development for treating rare diseases, including genetic disorders and complex lipid storage disorders. The company’s lead drug, Aegerion’s JUXTAPID® (lomitapide), is FDA approved and used to treat homozygous familial hypercholesterolemia (HoFH) - an ultra-rare genetic condition that affects fewer than one in a million people. JUXTAPID® is designed to reduce cholesterol levels in patients by blocking the production of low-density lipoprotein (LDL) - a type of harmful cholesterol.
Apart from their lead drug, Novelion Therapeutics has other promising drugs in their pipeline, including myalept® (metreleptin) - a treatment for lipodystrophy, which is currently FDA approved, and zuretinol acetate (QLT091001) for the treatment of the rare inherited retinal disease, Leber congenital amaurosis. Additionally, the company is developing a pipeline of treatments for other genetic diseases with unmet medical needs, such as late-onset LAL deficiency (Wolman disease and cholesteryl ester storage disease [CESD]), and Alagille syndrome, among others.
Novelion Therapeutics works closely with regulatory bodies, including the FDA, to ensure smooth and efficient product development and approval processes. The company's management team comprises seasoned executives who bring a vast amount of experience in different pharmaceutical sectors, including business development, operations, clinical development, and regulatory affairs.
In conclusion, Novelion Therapeutics Inc. is a biopharmaceutical company that is focused on developing and commercializing innovative treatments for rare genetic disorders. Their strong product portfolio, experienced leadership team, and commitment to working with regulatory bodies make them a promising company in the field of rare diseases.
Novelion Therapeutics Inc. is a dedicated biopharmaceutical company that specifically targets the treatment of rare diseases. The company is structured into distinct segments that focus on developing and commercializing therapies for patients suffering from these conditions. This comprehensive overview covers the critical segments, products, and services that Novelion Therapeutics offers.
Segments:
1. Aegerion Pharmaceuticals:
- Focus: This segment is primarily dedicated to the development and commercialization of therapies for rare and serious health conditions, particularly focusing on disorders such as familial hypercholesterolemia (FH), homozygous familial hypercholesterolemia (HoFH), and various forms of lipodystrophy.
- Role: Aegerion Pharmaceuticals plays a crucial role in addressing the unmet medical needs of patients with these rare genetic conditions through innovative treatment solutions.
2. Myalept:
- Focus: Myalept specifically concentrates on the development and commercialization of medications for rare metabolic disorders like lipodystrophy, a condition characterized by abnormal or degenerative conditions of the bodys adipose (fat) tissue.
- Role: This segment is integral in providing therapies aimed at restoring metabolic balance in affected patients, thereby enhancing their quality of life.
Products:
1. Juxtapid (lomitapide):
- Indication: Juxtapid is indicated for patients diagnosed with HoFH, a severe form of genetic hypercholesterolemia that leads to increased levels of LDL-C (low-density lipoprotein cholesterol).
- Mechanism of Action: Juxtapid works by inhibiting the microsomal triglyceride transfer protein (MTP), which is essential for the assembly of apolipoprotein B-containing lipoproteins in the liver and intestines. This action effectively reduces cholesterol absorption and production.
- Dosage Forms: Juxtapid is available in capsule formulations of 5 mg, 10 mg, and 20 mg, allowing for flexible dosing based on patient needs.
2. Myalept (metreleptin):
- Indication: Myalept is indicated for the treatment of lipodystrophy, particularly in patients who experience difficulties regulating their metabolism due to a lack of leptin, a hormone crucial for appetite and fat metabolism.
- Mechanism of Action: As a recombinant form of human leptin, Myalept directly addresses the deficiencies in leptin levels in patients, helping to normalize hunger and energy expenditure.
- Administration: The medication is administered via subcutaneous injection, allowing for direct delivery into the bloodstream for effective treatment.
Services:
1. Patient Support Programs:
- Overview: Novelion Therapeutics offers comprehensive patient support programs that guide and assist patients along their treatment journeys. These programs focus on helping patients understand their condition, adhere to treatment protocols, and manage potential side effects.
- Components: Services may include personalized education, access to resources, and ongoing communication with healthcare providers.
2. Medical Education Programs:
- Objective: The company provides extensive medical education initiatives aimed at healthcare professionals. These programs are designed to equip providers with the knowledge necessary to identify, diagnose, and manage rare diseases effectively.
- Content: Training sessions and workshops often cover the pathophysiology of rare conditions, the importance of early intervention, and best practices for treatment options.
3. Advocacy Support:
- Commitment: Novelion Therapeutics actively collaborates with advocacy groups and associations focused on raising awareness about rare diseases. This includes providing support in campaigns aimed at educating the public and fostering a better understanding of the challenges faced by patients.
- Outreach: The company works to ensure that the voices of patients and caregivers are heard, advocating for more significant research funding, improved healthcare access, and supportive policies.
Summary:
In conclusion, Novelion Therapeutics Inc. stands at the forefront of biopharmaceutical innovation, specializing in the treatment of rare diseases. With its focused segments, including Aegerion Pharmaceuticals and Myalept, the company develops and commercializes vital medications like Juxtapid and Myalept. Additionally, Novelion Therapeutics takes a holistic approach to patient care through a range of support services that include patient support programs, medical education for healthcare providers, and advocacy efforts, all aimed at improving the quality of life for those affected by rare metabolic disorders and hypercholesterolemia.
Segments:
1. Aegerion Pharmaceuticals:
- Focus: This segment is primarily dedicated to the development and commercialization of therapies for rare and serious health conditions, particularly focusing on disorders such as familial hypercholesterolemia (FH), homozygous familial hypercholesterolemia (HoFH), and various forms of lipodystrophy.
- Role: Aegerion Pharmaceuticals plays a crucial role in addressing the unmet medical needs of patients with these rare genetic conditions through innovative treatment solutions.
2. Myalept:
- Focus: Myalept specifically concentrates on the development and commercialization of medications for rare metabolic disorders like lipodystrophy, a condition characterized by abnormal or degenerative conditions of the bodys adipose (fat) tissue.
- Role: This segment is integral in providing therapies aimed at restoring metabolic balance in affected patients, thereby enhancing their quality of life.
Products:
1. Juxtapid (lomitapide):
- Indication: Juxtapid is indicated for patients diagnosed with HoFH, a severe form of genetic hypercholesterolemia that leads to increased levels of LDL-C (low-density lipoprotein cholesterol).
- Mechanism of Action: Juxtapid works by inhibiting the microsomal triglyceride transfer protein (MTP), which is essential for the assembly of apolipoprotein B-containing lipoproteins in the liver and intestines. This action effectively reduces cholesterol absorption and production.
- Dosage Forms: Juxtapid is available in capsule formulations of 5 mg, 10 mg, and 20 mg, allowing for flexible dosing based on patient needs.
2. Myalept (metreleptin):
- Indication: Myalept is indicated for the treatment of lipodystrophy, particularly in patients who experience difficulties regulating their metabolism due to a lack of leptin, a hormone crucial for appetite and fat metabolism.
- Mechanism of Action: As a recombinant form of human leptin, Myalept directly addresses the deficiencies in leptin levels in patients, helping to normalize hunger and energy expenditure.
- Administration: The medication is administered via subcutaneous injection, allowing for direct delivery into the bloodstream for effective treatment.
Services:
1. Patient Support Programs:
- Overview: Novelion Therapeutics offers comprehensive patient support programs that guide and assist patients along their treatment journeys. These programs focus on helping patients understand their condition, adhere to treatment protocols, and manage potential side effects.
- Components: Services may include personalized education, access to resources, and ongoing communication with healthcare providers.
2. Medical Education Programs:
- Objective: The company provides extensive medical education initiatives aimed at healthcare professionals. These programs are designed to equip providers with the knowledge necessary to identify, diagnose, and manage rare diseases effectively.
- Content: Training sessions and workshops often cover the pathophysiology of rare conditions, the importance of early intervention, and best practices for treatment options.
3. Advocacy Support:
- Commitment: Novelion Therapeutics actively collaborates with advocacy groups and associations focused on raising awareness about rare diseases. This includes providing support in campaigns aimed at educating the public and fostering a better understanding of the challenges faced by patients.
- Outreach: The company works to ensure that the voices of patients and caregivers are heard, advocating for more significant research funding, improved healthcare access, and supportive policies.
Summary:
In conclusion, Novelion Therapeutics Inc. stands at the forefront of biopharmaceutical innovation, specializing in the treatment of rare diseases. With its focused segments, including Aegerion Pharmaceuticals and Myalept, the company develops and commercializes vital medications like Juxtapid and Myalept. Additionally, Novelion Therapeutics takes a holistic approach to patient care through a range of support services that include patient support programs, medical education for healthcare providers, and advocacy efforts, all aimed at improving the quality of life for those affected by rare metabolic disorders and hypercholesterolemia.